Table 1

Patient groups in the study
Patient group Breast cancer and mutation status Number of patients Age in years, median (range) Genetic predisposition Parity Hormone use at time of surgery
Family history BRCA1 BRCA2 0 1 or 2 3 or 4 Data lacking HRT OC Data lacking
A Cancer, non-BRCA1/2 21 50 (31–77) 4 NA NA 8 4 9 0 3 1 0
B Cancer, BRCA1 17 43 (23–81) 17 17 NA 4 10 0 3 4 1 3
C Cancer, BRCA2 11 51 (33–74) 11 NA 11 0 7 3 1 0 1 2
D Prophylactic mastectomy, BRCA1 12 37 (23–54) 12 12 NA 0 6 4 1 0 4 1
E Prophylactic mastectomy, BRCA2 11 37 (31–51) 11 NA 11 0 5 5 1 0 0 1
F Mammoplasty, non-cancer, non-BRCA 34 31 (20–68) 5 NA NA 19 7 8 0 0 8 1

Patient groups included in the study and subsequently re-grouped according to the listed parameters for analysis of ALDH+ cells. The table presents selected clinical, genetic, and hormonal characteristics of patients.

NA, not applicable; HRT, hormone replacement therapy; OC, oral contraceptive.

Isfoss et al.

Isfoss et al. BMC Clinical Pathology 2013 13:28   doi:10.1186/1472-6890-13-28

Open Data